Psoriatic arthritis patients who switch anti-TNFi drugs fare worse

04/26/2013 | Family Practice News

Patients with psoriatic arthritis who switched to a second anti-tumor necrosis factor inhibitor drug had lower drug-survival rates at three years compared with those who remained on their first medication, researchers in Norway found. Switchers also showed much poorer responses in factors such as Disease Activity Score-28 remission and American College of Rheumatology-50 response than non-switchers. The findings were published in the journal Annals of the Rheumatic Diseases.

View Full Article in:

Family Practice News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX